Skip to main content
Smart Investors Daily
VR

NASDAQ · VRNA

Verona Pharma plc

Healthcare · Biotechnology

$106.91

Up+$0.12 (+0.11%)

Updated Oct 5, 2026, 3:33 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
72.68B
P/E ratio
-145.11
Dividend yield
0.00%
52-week range
— – —
Volume
1.87M
Avg. volume
3.56M

Price performance · VRNA

VRNA price history

1M range · 0 trading sessions · Daily adjusted prices

VRNA does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest VRNA news

The latest Smart Investors Daily articles mentioning VRNA.

VRNA research

Overview

Company profile and research snapshot.

Company profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$145.67
Implied upside
—
Analysts
5
VRNA recent ratings
DateFirmRatingTarget
Jul 14, 2025HC Wainwright & Co.Neutral—
Jul 10, 2025Wells FargoEqual-Weight—
Jul 10, 2025BTIGNeutral—
Jul 9, 2025Canaccord GenuityHold—
Jul 9, 2025JefferiesHold—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.